Saturday 17 October 2026
Export AYTU’s income statement to Excel — free account
Aytu BioPharma, Inc.
AYTU Healthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.
2.04
0.03
+1.49%
Follow AYTU
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| (52.55%) | (97.24%) | (108.72%) | (49.33%) | ||
| (12.44%) | (28.87%) | (20.52%) | (10.86%) | ||
ROIC |
(19.99%) | (31.33%) | (106.20%) | (29.63%) | |
Return on Tangible Assets |
(190.36%) | (438.80%) | (218.98%) | (83.70%) | |
Average Days of Receivables |
144.42 | 157.93 | 180.19 | 190.39 | |
Free Cash Flow per Share |
0.26 | 0.15 | (0.06) | (0.14) | |
Free Cash Flow |
3.24 | 1.58 | (0.55) | (1.36) | |
Capital Expenditures |
(0.05) | (0.10) | 0.04 | — | |
| Other line items | |||||
Cash ROIC |
4.12% | 1.88% | (0.85%) | (1.65%) | |
Accounts Receivable Turnover |
2.13 | 1.88 | 2.22 | 2.26 | |
Accounts Payable Turnover |
1.90 | 1.58 | 1.60 | 1.60 | |
Inventory Turnover |
2.27 | 2.15 | 2.10 | 1.89 | |
Average Days of Payables |
198.47 | 241.93 | 250.58 | 218.00 | |
Days of Inventory on Hand |
120.66 | 136.58 | 152.12 | 178.40 | |
Tax Rate |
0.03 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 1.59% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
74.07% | 71.90% | 62.41% | 59.26% | |
Share Based Compensation of Revenue |
1.20% | 1.16% | 1.04% | 0.81% | |
Interest Coverage |
(4.39) | (6.76) | (3.21) | (2.60) | |
Operating CF/Net income |
(0.23) | (0.05) | 0.02 | 0.10 | |
Depreciation/Fixed assets |
10.50 | 10.77 | 9.40 | 9.91 | |
Capex/Depreciation |
(0.01) | (0.02) | 0.01 | 0.00 | |
Revenue per Share |
4.67 | 5.38 | 6.24 | 6.75 | |
Operating CF per Share |
0.27 | 0.16 | (0.06) | (0.14) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026